X
No Ads. No Trackers. No Kidding! (Learn More)
Loading...
Bristol-Myers Squibb Co.'s decision to hold off launching Zeposia, its newly approved multiple sclerosis treatment, underscores how disruptive the COVID-19... [Read More]
PRINCETON, N.J.--(BUSINESS WIRE)--Mar 27, 2020... [Read More]
Thumbnail
The pharma giant has been tossed into the discount bin, but that's not the only reason to consider buying its shares. [Read More]
The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Let's conquer your financial goals together...faster. See... [Read More]
Thumbnail
Bristol-Myers Squibb's (NYSE: BMY) cardiovascular drug sales have surged 326% from $1.9 billion in 2015 to $7.9 billion in 2019, with the massive success of... [Read More]
Thumbnail
The drug Zaposia is being brought to market by Bristol Myers Squibb... [Read More]
Thumbnail
Bristol-Myers Squibb will delay a sales push for its newly approved multiple sclerosis drug amid the coronavirus crisis... [Read More]
Bristol-Myers Squibb (NYSE:BMY) and Acceleron Pharma (NASDAQ:XLRN) announce that the New England Journal of Medicine has published results from BELIEVE, the Phase 3 study evaluating... [Read More]
Bristol-Myers Squibb Co said on Thursday the U.S. Food and Drug Administration a... [Read More]
NEW YORK--(BUSINESS WIRE)--Mar 26, 2020... [Read More]
Shares of Bristol-Myers Squibb Co. gained 1% in premarket trading on Thursday after the drugmaker said the Food and Drug Administration had approved Zeposia,... [Read More]
Shares of Bristol-Myers Squibb Co. BMY, +0.22% ... [Read More]
PRINCETON, N.J.--(BUSINESS WIRE)--Mar 26, 2020... [Read More]
The FDA approves Bristol-Myers Squibb's (NYSE:BMY) oral Zeposia (ozanimod) 0.92 mg for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically... [Read More]
Bristol-Myers Squibb (NYSE: BMY) could see a 40% upside from the current levels, per our price estimate of $68, which is based on expected 2020... [Read More]
Sales of Bristol-Myers Squibb Co's cancer drug Abraxane have been suspended... [Read More]
China has suspended sale, import and use of Bristol-Myers Squibb Co's cance... [Read More]
Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers Squibb (BMY), BHP Group (BHP) and CVS Health (CVS). [Read More]
PRINCETON, N.J.--(BUSINESS WIRE)--Mar 23, 2020... [Read More]
Loading...
Save As
Preview
Preview